TABLE 1. Patient Demographics and Baseline Characteristics.
| Demographics | N = 147 |
|---|---|
| Median age (range), y | 66 (25-89) |
| Sex, n (%) | |
| Male | 74 (50) |
| Female | 73 (50) |
| Race, n (%) | |
| White | 135 (92) |
| Black or African American | 8 (5) |
| Asian | 1 (1) |
| Other | 3 (2) |
| Emetogenic risk, n (%) | |
| HEC | 71 (48) |
| MEC | 76 (52) |
| ECOG PS at baseline, n (%) | |
| 0 | 116 (79) |
| 1 | 22 (15) |
| 2 | 8 (5) |
| 3 | 1 (1) |
| Type of cancer, n (%) | |
| Colorectal | 43 (29) |
| Lung | 34 (23) |
| Breast | 17 (12) |
| Pancreatic | 10 (7) |
| Esophageal | 10 (7) |
| Othera | 33 (23) |
| Route of administration, n (%) | |
| Central | 80 (54) |
| Peripheral | 67 (46) |
| Previous radiation therapy, n (%) | |
| No | 119 (81) |
| Yes | 28 (19) |
| 5-HT3 RA therapy, n (%) | |
| GERSC | 99 (67) |
| Palonosetron | 43 (29) |
| Granisetron | 1 (1) |
| GERSC and palonosetron | 1 (1) |
| None | 3 (3) |
| HTX-019 doses, n (mean) | 864 (6) |
Abbreviations: 5-HT3 RA, 5-hydroxytryptamine type 3 (serotonin) receptor antagonist; ECOG PS, Eastern Cooperative Oncology Group performance status; GERSC, granisetron extended release subcutaneous; HEC, highly emetogenic therapy; MEC, moderately emetogenic therapy; y, years.
aAstrocytoma, basal cell carcinoma, B-cell lymphoma, bladder, cardiac neoplasm, cervical, stomach, head and neck, uterine, leukemia/lymphoma, non-Hodgkin's lymphoma, ovarian, parotid gland neoplasm, prostate, renal, pelvic, bile duct, multiple myeloma, salivary gland, and T-cell lymphoma.